Try our Advanced Search for more refined results

INDIVIOR INC. et al v. DR. REDDY'S LABORATORIES S.A. et al

  1. June 24, 2022

    Dr. Reddy's Gets $72M In Generic Suboxone Settlement

    Indivior, Aquestive and Dr. Reddy's Laboratories have ended their yearslong litigation battle over generic versions of the opioid addiction treatment Suboxone, with the Indian drugmaker on Friday saying it will receive $72 million by April 2024.

  2. August 28, 2018

    Teva Can't Move IP Suits Over Opioid Treatment Drug To Del.

    A New Jersey federal judge on Monday refused to transfer to Delaware a group of Indivior Inc.'s lawsuits that accuse Dr. Reddy's Laboratories, Teva Pharmaceuticals and Alvogen Pine Brook Inc. of pursuing generic versions of brand name opioid addiction treatment drug Suboxone, infringing its patents.

  3. July 13, 2018

    Indivior Wins Bid To Block Sales Of Suboxone Generic

    Determining that drugmaker Indivior will likely be able to show its suit claiming infringement by Dr. Reddy's of a so-called child patent covering its Suboxone Film will not be precluded by a suit in which Dr. Reddy's was cleared of infringement of the parent patent, a New Jersey federal judge on Friday granted Indivior a preliminary injunction blocking sales.